Zapata Quantum, Inc.ZPTA

Quantum Pilot applies agentic AI to quantum resource estimation via NVIDIA collaboration.

“Drawing on Zapata’s experience developing quantum algorithms and applications across industries and hardware architectures, Quantum Pilot combines a proprietary knowledge framework with advanced computational tools, including capabilities developed through its collaboration with NVIDIA to apply agentic AI to quantum resource estimation. The platform also builds on Zapata’s collaboration with the University of Maryland on formal methods for quantum software verification.”

Quantum Graph provides structured context for the platform and its AI agents.

“Quantum Graph , a proprietary knowledge layer that connects quantum applications, algorithms, research, and hardware roadmaps, providing structured context for the platform and its AI agents as the field advances.”

Zapata collaborated with NVIDIA using agentic AI for quantum algorithm discovery.

“During Kapur’s tenure, Zapata has collaborated with NVIDIA, using agentic AI to accelerate quantum algorithm discovery. The Company’s quantum-enabled drug discovery research with Dana-Farber Cancer Institute, the University of Toronto and Insilico Medicine was also recognized as one of Nature Biotechnology’s Top 10 Papers of 2025, reflecting Zapata’s longstanding scientific leadership and contribution to Boston’s biotechnology research community.”

Zapata partners with NVIDIA to apply agentic AI for quantum algorithm development.

“The collaboration also reflects Zapata’s broader strategy of working with technology leaders across the quantum and AI ecosystems, including its recently announced ongoing partnership with NVIDIA to apply agentic AI to accelerate quantum algorithm development.”

Mr. Golestani serves on the board of Iridius.ai, a next-generation agentic AI platform.

“Previously, from June 1994 to April 2018, Mr. Golestani served in multiple positions at Merck & Co. (NYSE: MRK) (“Merck”), a multinational pharmaceutical company, where he was responsible for, among other things, Merck’s portfolio of digital health services and solutions companies, most recently as President, Emerging Businesses and Global Chief Information Officer, prior to his retirement in April 2018. Mr. Golestani also serves as a member of the board of directors of a number of companies, including: eMids, a consulting firm that provides IT and business process management solutions to the healthcare industry, since April 2020; Emmes, a clinical research organization, since March 2021; Iridius.ai, a next-generation agentic AI platform accelerating innovation in the world's most regulated industries, since September 2025; Otonoma, a secure platform that powers the next generation of digital operations with its Paranet system, since August 2024. Mr. Golestani also previously served as a director on the boards of a number of companies, including: Sparta Systems, Inc. as Chairman, an enterprise quality management software provider that was acquired by Honeywell, Inc. (April 2018 to February 2021); CIOX Health, a healthcare information management company (September 2018 to October 2021); Molecula Corp., an artificial intelligence and data analytics company which was acquired by Circuit.ai (September 2020 to June 2024); Toposware Inc., a developer of blockchain technology acquir”

Zapata Quantum is collaborating with NVIDIA to apply agentic AI for quantum algorithm development.

“Collaboration with NVIDIA to apply agentic AI to accelerate quantum algorithm development: The initiative targets the creation of a scalable automated system for quantum resource estimation, a major bottleneck in quantum application development.”

Director serves on board of Iridius.ai, described as a next-generation agentic AI platform.

“Previously, from June 1994 to April 2018, Mr. Golestani served in multiple positions at Merck & Co. (NYSE: MRK) (“Merck”), a multinational pharmaceutical company, where he was responsible for, among other things, Merck’s portfolio of digital health services and solutions companies, most recently as President, Emerging Businesses and Global Chief Information Officer, prior to his retirement in April 2018. Mr. Golestani also serves as a member of the board of directors of a number of companies, including: eMids, a consulting firm that provides IT and business process management solutions to the healthcare industry, since April 2020; Emmes, a clinical research organization, since March 2021; Iridius.ai, a next-generation agentic AI platform accelerating innovation in the world's most regulated industries, since September 2025; Otonoma, a secure platform that powers the next generation of digital operations with its Paranet system, since August 2024. Mr. Golestani also previously served as a director on the boards of a number of companies, including: Sparta Systems, Inc. as Chairman, an enterprise quality management software provider that was acquired by Honeywell, Inc. (April 2018 to February 2021); CIOX Health, a healthcare information management company (September 2018 to October 2021); Molecula Corp., an artificial intelligence and data analytics company which was acquired by Circuit.ai (September 2020 to June 2024); Toposware Inc., a developer of blockchain technology acquir”

Mr. Golestani serves on the board of Iridius.ai, a next-generation agentic AI platform.

“Previously, from June 1994 to April 2018, Mr. Golestani served in multiple positions at Merck & Co. (NYSE: MRK) (“Merck”), a multinational pharmaceutical company, where he was responsible for, among other things, Merck’s portfolio of digital health services and solutions companies, most recently as President, Emerging Businesses and Global Chief Information Officer, prior to his retirement in April 2018. Mr. Golestani also serves as a member of the board of directors of a number of companies, including: eMids, a consulting firm that provides IT and business process management solutions to the healthcare industry, since April 2020; Emmes, a clinical research organization, since March 2021; Iridius.ai, a next-generation agentic AI platform accelerating innovation in the world's most regulated industries, since September 2025; Otonoma, a secure platform that powers the next generation of digital operations with its Paranet system, since August 2024. Mr. Golestani also previously served as a director on the boards of a number of companies, including: Sparta Systems, Inc. as Chairman, an enterprise quality management software provider that was acquired by Honeywell, Inc. (April 2018 to February 2021); CIOX Health, a healthcare information management company (September 2018 to October 2021); Molecula Corp., an artificial intelligence and data analytics company which was acquired by Circuit.ai (September 2020 to June 2024); Toposware Inc., a developer of blockchain technology acquir”

Director serves on board of Iridius.ai, a next-generation agentic AI platform.

“Previously, from June 1994 to April 2018, Mr. Golestani served in multiple positions at Merck & Co. (NYSE: MRK) (“Merck”), a multinational pharmaceutical company, where he was responsible for, among other things, Merck’s portfolio of digital health services and solutions companies, most recently as President, Emerging Businesses and Global Chief Information Officer, prior to his retirement in April 2018. Mr. Golestani also serves as a member of the board of directors of a number of companies, including: eMids, a consulting firm that provides IT and business process management solutions to the healthcare industry, since April 2020; Emmes, a clinical research organization, since March 2021; Iridius.ai, a next-generation agentic AI platform accelerating innovation in the world's most regulated industries, since September 2025; Otonoma, a secure platform that powers the next generation of digital operations with its Paranet system, since August 2024. Mr. Golestani also previously served as a director on the boards of a number of companies, including: Sparta Systems, Inc. as Chairman, an enterprise quality management software provider that was acquired by Honeywell, Inc. (April 2018 to February 2021); CIOX Health, a healthcare information management company (September 2018 to October 2021); Molecula Corp., an artificial intelligence and data analytics company which was acquired by Circuit.ai (September 2020 to June 2024); Toposware Inc., a developer of blockchain technology acquir”